Blue Earth Diagnostics Highlights Presentations on POSLUMA (Flotufolastat F 18) in Prostate Cancer at Upcoming ASTRO Annual Meeting
Imaging Technology
SEPTEMBER 27, 2023
PET imaging with POSLUMA reveals clinical information crucial to decision-making for men with prostate cancer, and we are excited to share further information with the radiation oncology community at ASTRO 2023,” said David E. Gauden , D.Phil., Chief Executive Officer of Blue Earth Diagnostics. Kuo, MD, Ph.D., Ulaner, MD, Ph.D.,
Let's personalize your content